Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
240 CHF | +1.35% | +0.84% | -8.19% |
Apr. 25 | The specter of stagflation rears its ugly head again | |
Apr. 25 | ROCHE : Barclays lowers target price | CF |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's enterprise value to sales, at 3.14 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.18% | 193B | - | ||
+25.07% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+13.42% | 233B | B+ | ||
+5.62% | 201B | B- | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ | ||
+0.62% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RO Stock
- Ratings Roche Holding AG